Impact of β-lactamases on the clinical use of β-lactam antibiotics

International Journal of Antimicrobial Agents

Volumn 7, Issue SUPPL., 1996, Pages

  Nicolas Chanoine, M H ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Lactam antibiotic; Lactamase

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFAMANDOLE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; CLAVULANIC ACID; METRONIDAZOLE; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CONFERENCE PAPER; DRUG USE; HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0029783532     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(96)00315-9     Document Type: Conference Paper

References (72)

1. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature (London) 1940;146:837.
2. Sanders CC, Sanders WE. β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824-839.
3. Frère JM. Beta-lactamases and bacterial resistance to antibiotics. Mol Microbiol 1995;16:385-395.
4. Livermore DM, Yang YJ. β-Lactamase-lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987;155:775-782.
5. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. Proc Natl Acad Sci USA 1994;91:7693-7697.
6. Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994;38:1262-1270.
7. Gonzalez Leiza M, Perez-Diaz JC, Ayala J, Casellas JM, Martinez-Beltran J, Bush K, Baquero F. Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid-mediated β-lactamase with two molecular variants. Antimicrob Agents Chemother 1994;38:2150-2157.
8. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated β-lactamase (MIR-I) conferring resistance to oxyimino- and a-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990;34:2200-2209.
9. LAT-1) found in Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:2207-2209.
10. Bakken JS, Sanders CC, Clark RB, Hori M. Beta-lactam resistance in Aeromonas spp. caused by inducible β-lactamases active against penicillins, cephalosporins, and carbapenems. Antimicrob Agents Chemother 1988;32:1314-1319.
11. Felici A, Perilli M, Segatore B, Franceschini N, Setacci D, Oratore A, Stefani S, Galleni M, Amicosante G. Interactions of biapenem with active-site serine and metallo-β-lactamases. Antimicrob Agents Chemother 1995;39:1300-1305.
12. Saino Y, Kobayashi F, Inoue M, Mitsuhashi S. Purification and properties of inducible penicillin β-lactamase isolated from Pseudomonas maltophila. Antimicrob Agents Chemother 1982;22:564-570.
13. Jacoby GA, Sutton I. β-Lactamases and β-lactam resistance in Escherichia coli. Antimicrob Agents Chemother 1985;28:703-706.
14. Mederios AA, O'Brien TF. Mechanisms of resistance to cephalosporins in ampicillin-resistant Escherichia coli. J Infect Dis 1973;128(suppl):S335-S340.
15. Livermore DM. Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 β-lactamase. J Antimicrob Chemother 1992;29:219-232.
16. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
17. Martinez JL, Vicente MF, Delgado-Ibarren A, Perez-Diaz JC, Baquero F. Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother 1989;33:595.
18. Shannon K, Williams H, King A, Phillips I. Hyperproduction of TEM-1 β-lactamase in clinical isolates of Escherichia coli serotype 015. FEMS Microbiol Lets 1990;67:319-324.
19. Chardon H, Farzaneth S, Labia R, Jarlier V, Nicolas MH, Paul G, Poyart C, Sirot D, Sirot J. Analysis of β-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin clavulanic acid. J Antimicrob Chemother 1995;36:267-269.
20. Henquell C, Chanal C, Sirot D, Labia R, Sirot J. Molecular characterization of 9 different types of mutants among 107 inhibitor-resistant TEM (IRT) from clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1995;39:427-430.
21. Henquell C, Sirot D, Chanal C, De Champs C, Chatron P, Lafeuille B, Texier P, Sirot J, Cluzel R. Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother 1994;34:707-714.
22. Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 1995;39:899-905.
23. Morosini MI, Canton R, Martinez-Beltran J, Negri MC, Perez-Diaz JC, Baquero F, Blazquez J. New extended-spectrum TEM-type β-lactamase from Salmonella enterica subsp. enterica isolated in a nosocomial outbreak. Antimicrob Agents Chemother 1995;39:458-461.
24. Philippon AR, Labia R, Jacoby GA. Extended spectrum β-lactamases. Antimicrob Agents Chemother 1989;33:1131-1136.
25. Shah PM, Asanger R, Kahan FM. Incidence of multi-resistance in Gram-negative aerobes from intensive care units of 10 German hospitals. Scand J Infect Dis 1991;78(suppl):22-34.
26. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R. Transferable resistance to third generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 1987;20:323-334.
27. Lacey RW. Antibiotic resistance in Staphylococcus aureus and streptococci. Br Med Bull 1984;40:77-83.
28. Murray BE, Mederski-Samoraj B. Transferable β-lactamase: a new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168-1171.
29. McGowan JE. Abrupt changes in antibotic resistance. J Hosp Infect 1991;18(suppl A):202-210.
30. Blaisot B, Mackie M, Sednaoui P, Goulet V, Catalan F. Le gonocoque en France en 1989. Bull Epidemiol Hebdo 1990;52:223-225.
31. Sedanaoui P, Goulet V, Alonso JM. National surveillance of antimicrobial resistance of Neisseria gonorrhoeae in France. Abstract 1310, Proceedings of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 1995.
32. Centers for Diseases Control. Antibiotic resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection management and control. Morbid Mortal Wkly Rep 1987; 36:1S-18S.
33. Doern GV, Jorgensen JH, Thornsberry C, Preston DA, Tubert T, Redding JS, Maher LA. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother 1988;32:180-185.
34. Machka K, Braveny I, Dabernat H, Dornbusch K, Van Dyck E, Kayser FH, Van Klingeren B, Mittermayer H, Perea E, Powell M. Distribution and resistance patterns of Haemophilus influen-zae: a European cooperative study. Eur J Clin Microbiol Infect Dis 1988;7:14-24.
35. Calder MA, Croughan MJ, McLeod DT, Ahmad F. The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections. Drugs 1986;31(suppl 3):11-16.
36. Fung CP, Yeo SF, Livermore DM. Susceptibility to Moraxella catarrhalis isolates to β-lactam antibiotics in relation to β-lactamase type. J Antimicrob Chemother 1994;33:215-222.
37. Shurin PA, Marchant CD, Kim CH, Van Hare GF, Johnson CE, Tutihasi MA, Knapp LJ. Emergence of β-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media. Pediatr Infect Dis 1983;2:34-38.
38. Kaleida PH, Bluestone CD, Rockette HE, Bass LW, Wolfson JH, Breck JM, Ubinger EB, Rohn DD. Amoxicillin-clavulanate potassium comparison with cefaclor for acute otitis media in infants and children. Pediatr Infect Dis J 1987;6:265-271.
39. Marchant CD, Shurin PA, Johnson CE, Murdell-Panek D, Feinstein JC, Fulton D, Flexon P, Carlin SA, Van Hare GF. A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media. J Pediatr 1986;109:891-896.
40. Odio CM, Kusmiesz H, Shelton S, Nelson JD. Comparative treatment trial of augmentin versus cefaclor for acute otitis media with effusion. Pediatrics 1985;75:819-826.
41. Hart CA, Cuevas LE, Marzouk O, Thomson APJ, Sills J. Management of bacterial meningitis. J Antimicrob Chemother 1993;32(suppl A):49-59.
42. Peltola H, Antilla M, Renkonen OK. Randomised comparison of chloramphenicol, ampicillin, cefotaxime and ceftriaxone for childhood bacterial meningitis. Lancet 1989;i:1281-1287.
43. Shann F, Barker J, Poore P. Chloramphenicol alone versus chloramphenicol plus penicillin for bacterial meningitis in children. Lancet 1985;ii:681-701.
44. Winrich AE, Del Bene VE. Beta-lactamase activity in anaerobic bacteria. Antimicrob Agents Chemother 1976;10:106-111.
45. Nathens AB, Rotstein OD. Therapeutic options in peritonitis. Surgical Infections 1994;74:677-692.
46. Turner P, Edwards R, Weston V, Gazis A, Ispahani P, Greenwood D. Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis. Lancet 1995;345:1275-1277.
47. Liu PYF, Gur D, Hall LMC, Livermore DM. Survey of the prevalence of β3-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother 1992;30:429-447.
48. Buirma RJA, Horrevorts AM, Wagenvoort JHT. Incidence of multi-resistant Gram-negative isolates in eight Dutch hospitals. Scand J Infect Dis 1991;78(suppl):35-44.
49. Blazquez J, Baquero MR, Canton R, Alos I, Baquero F. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother 1993;37:2059-2063.
50. Vedel G, Belaaouaj A, Gilly L, Labia R, Philippon A, Nevot P, Paul G. Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. J Antimicrob Chemother 1992;30: 449-462.
51. Roy C, Segura C, Torrellas A, Reig R, Teruel D, Hermida M. Activity of amoxycillin/clavulanate against β-lactamase-producing Escherichia coli and Klebsiella spp. J Antimicrob Chemother 1989;24(suppl B):41-47.
52. Sirot DL, Goldstein FW, Soussy CJ, Courtieu AL, Husson MO, Meyran M, Morel C, Perez R, Quentin Noury C, Reverdy ME, Sheftel JM, Rosembaum M, Revzani Y. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 1992;36:1677-1681.
53. Ariel G, Rouveau M, Casin I, Bouvet PJM, Lagrange PH, Philippon A. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J Clin Microbiol 1994;32:2553-2558.
54. de Champs C, Sirot D, Chanal C, Poupart C, Dumas MP, Sirot J. Concomitant dissemination of three extended-spectrum β-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother 1991;29:590-592.
55. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern. Rev Infect Dis 1988;10:867-878.
56. Nouvellon M, Pons JL, Sirot D, Combe ML, Lemeland JF. Clonal outbreaks of extended-spectrum β-lactamase-producing strains of Klebsiella pneumoniae demonstrated by antibiotic susceptibility testing, β-lactamase typing, and multilocus enzyme electrophoresis. J Clin Microbiol 1994;32:2625-2627.
57. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992;29(suppl A):19-24.
58. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoine MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995;274:639-644.
59. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995;35:521-534.
60. Thabaut A, Philippon A, Meyran M. β-Lactamases of Pseudomonas aeruginosa and susceptibility against β-lactam antibiotics. Chemotherapia 1985;1:36-42.
61. Livermore DM. Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother 1993;31(suppl A):9-21.
62. Lindberg F, Normark S. Contribution of chromosomal β-lactamases to β-lactam resistance in enterobacteria. Rev Infect Dis 1986;8(suppl):S292-S304.
63. Honoré N, Nicolas MH, Cole ST. Regulation of enterobacterial cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO 1986;5:3709-3714.
64. Honoré N, Nicolas MH, Cole ST. Regulation of enterobacterial cephalosporinase production: the role of a membrane-bound sensory transducer. Mol Microbiol 1989;3:1121-1130.
65. Bennett PM, Chopra I. Molecular basis of β-lactamase induction in bacteria. Antimicrob Agents Chemother 1993;37:153-158.
66. Nicolas MH, Honoré N, Jarlier V, Philippon A, Cole ST. Molecular genetic analysis of cephalosporinase production and its role in β-lactam resistance in clinical isolates of Enterobacter cloacae. Antimicrob Agents Chemother 1987;31:295-299.
67. Findell CM, Sherris JC. Susceptibility of Enterobacter to cefamandole: evidence for high mutation rate to resistance. Antimicrob Agents Chemother 1976;9:970-974.
68. Lampe MF, Allan BJ, Minshew BH, Sherris JC. Mutational enzymatic resistance of Enterobacter species to β-lactam antibiotics. Antimicrob Agents Chemother 1982;21:655-660.
69. Cole ST, Nicolas MH. β-Lactam resistance mechanisms in Gram-negative bacteria. Microbiol Sci 1986;3:334-339.
70. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK. J Med Microbiol 1995;43:300-309.
71. Cassinat B, Nicolas MH. Comparison of antibiotic combinations against penicillin-resistant pneumococci. J Antimicrob Chemother 1994;34:785-790.
72. Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L. Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother 1991;35:1093-1098.